Skip to main content
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
      • Efgartigimod
      • Cusatuzumab
      • ARGX-117
      • ARGX-118
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us

Breadcrumb

  1. Home
  2. Investors
  3. AFM filings

AFM filings

 

05/28/2020
Summary Document
05/28/2020
Summary Document - Dutch Translation
05/28/2020
Securities Note
05/28/2020
Amendment to Universal Registration Document
09/20/2018
Admission to listing and trading of new ordinary shares
03/26/2018
Registration Document
04/22/2017
Admission to listing and trading of new ordinary shares
06/02/2016
Registration Document
05/31/2016
Listing of shares on Euronext Brussels
06/20/2014
Initial Offering of Shares
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
      • Efgartigimod
      • Cusatuzumab
      • ARGX-117
      • ARGX-118
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us
2021 © Argenx
Disclaimer
Privacy policy
You are now leaving the argenx web site

This link will take you to a site maintained by a third party, which is responsible for its contents.

OK